A trial looking at vinflunine for advanced bladder cancer
Cancer type:
Status:
Phase:
This trial was looking at a new chemotherapy drug called vinflunine to treat advanced bladder cancer.
Doctors may use chemotherapy to treat transitional cell bladder cancer that has spread. In this trial, the researchers wanted to see if vinflunine helps people with advanced transitional cell bladder cancer that has come back or got bigger after treatment with
The aims of the trial were
- To find out how well vinflunine works for treating advanced transitional cell bladder cancer
- To learn more about the side effects
Summary of results
From their analysis of results in 2006, the research team say that vinflunine can help people with advanced transitional cell cancer, without causing too many serious side effects.
The trial recruited 51 people. Everybody taking part had vinflunine at least once. The average number of treatments was 4.
- In 9 people the cancer slowed or stopped growing - researchers call this
partial response - In 25 people the cancer remained the same - researchers call this
stable disease - In 14 people the cancer continued to grow
- The researchers did not have results for 3 people
The main side effects were a drop in the number of blood cells and constipation, each of which affected about 2 thirds of people.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Nick James
Supported by
Pierre Fabre Medicament
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040